Welte, Thomas
Arnold, Frederic
Westermann, Lukas
Rottmann, Felix A.
Hug, Martin J.
Neumann-Haefelin, Elke
Ganner, Athina
Funding for this research was provided by:
Universitätsklinikum Freiburg
Article History
Received: 25 September 2022
Accepted: 3 January 2023
First Online: 11 January 2023
Declarations
:
: All patients gave informed consent for eculizumab treatment. This study is in conformity with the Helsinki and Istanbul declarations and its amendments. The study was approved by the Ethics Committee of the University Medical Center, Freiburg, Germany (reference number 22–1278-S1-retro). The study was registered in the German Clinical Trials Register (DRKS00030164) on 09/15/2022.
: Not applicable.
: The authors declare that they have no financial and non-financial competing interests.